Open AccessAumolertinib challenge as an optional treatment in advanced non small‑cell lung cancer after osimertinib failure with epidermal growth factor receptor‑sensitive mutation: A case series
Author(s) -
Xinjing Ding,
Jianghua Ding,
Zhaohui Leng,
Yun Song
Publication year - 2022
Publication title -
oncology letters
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.766
H-Index - 54
eISSN - 1792-1082
pISSN - 1792-1074
DOI - 10.3892/ol.2022.13520
Subject(s) - osimertinib , epidermal growth factor receptor , molecular medicine , cancer research , a431 cells , oncogene , lung cancer , cell cycle , epidermal growth factor , cancer , medicine , oncology , biology , receptor , erlotinib
Accelerating Research
Robert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom
Address
John Eccles HouseRobert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom